Centinel Spine, Inc. has announced that it has hit a milestone of 20, 000 of implantations of STALIF C cervical Integrated Interbody devices. The STALIF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders. According to the company, the procedure is attractive to surgeons because it involves a single incision procedure that is minimally invasive and tissue sparing.
Centinel Spine Reaches 20, 000 Implantations of STALIF C
2 min read Premium comments
Secondary
“This is an important milestone for Centinel Spine and our STALIF C product family. It represents our proven success and heritage of healing in anterior column support procedures, ” said Centinel CEO and President John Viscogliosi in the June 1, 2015 news release. “We are pleased at the continued adoption of our STALIF technology as we strive to meet our vision of becoming the leading anterior column support spine franchise.”
The news release indicates, “This design also allows the device to nest fully within the confines of the vertebral body, leaving the anatomy unchanged external to the interbody. The STALIF C three-screw construct features the Anti Back-Out technology, provides compressive fixation at the graft site and is proven to be biomechanically equivalent to a cage and plate.”
Viscogliosi told OTW, “The milestone of exceeding 20, 000 implantations of our STALIF C, Integrated Interbody cervical device is a very exciting milestone for Centinel Spine. It further validates our over 25 years of clinical success in anterior column support and healing, which began with the first lumbar cage the Hartshill Horseshoe.”
“Centinel Spine continues to work to define, through clinical success and published biomechanical studies, Integrated Interbody devices STALIF C and STALIF C-Ti (Ti-ACTIVE coated device) as the standard of care in cervical fusion procedures. The STALIF C product family with its recent allogeneic bone graft indication fuel our momentum in achieving this goal.”
As for details about the Anti Back-Out technology, Viscogliosi noted, “Anti Back-Out Technology (ABO) is proprietary to Centinel Spine. It provides our surgeon partners and their patients additional security and peace-of-mind from potential screw backout. This feature is a spilt-ring titanium technology that automatically deploys and compresses upon screw insertion. We do not lock or fixate our screw because we believe it may interfere with the bone remodeling process. The ABO feature allows the screw to toggle during the healing process, which should help reduce stress-shielding effect.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.